Brenetafusp + chemotherapy

Brenetafusp is a novel ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) bispecific protein that targets PRAME (PReferentially expressed Antigen in Melanoma), an antigen presented by HLA-A*02:01 on tumor cells. It works by forming a bridge between T-cells and cancer cells, triggering T-cell activation and the release of cytotoxic molecules such as perforin and granzymes, which induce apoptosis in the targeted cancer cells[1][8]. In clinical studies, brenetafusp has demonstrated activity both as monotherapy and in combination with chemotherapy for heavily pre-treated, platinum-resistant ovarian cancer patients[2][5]. The combination with chemotherapy may enhance clinical activity by increasing antigen presentation machinery expression in tumor cells. Brenetafusp is also being investigated for other solid tumors including cutaneous melanoma, non-small cell lung cancer, small cell lung cancer, synovial sarcoma, and endometrial cancers[3][4][8].